Explore our kidney trials and find opportunities to take part in advancing medical research. Listings change as protocols open and close.
Study-related visits, tests, and investigational therapy are provided at no cost, and your insurance is never billed. Filter by condition to see what may fit.
Baxdrostat in combination with dapagliflozin, evaluated for renal outcomes and cardiovascular mortality in chronic kidney disease (BaxDuo-Pacific).
Who it is forAdults with chronic kidney disease and high blood pressure.
Extended TARPEYO® (delayed-release budesonide) treatment in adults with primary IgA nephropathy (NefXtend).
Who it is forAdults with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg.
These studies continue with participants already enrolled.
Lepodisiran for cardiovascular risk reduction in adults with high lipoprotein(a) (ACCLAIM-Lp(a)). Enrollment closed; participants are followed through 2029.
Retatrutide's effect on cardiovascular and kidney outcomes in adults living with obesity (TRIUMPH-Outcomes). Enrollment closed; participants are followed through 2029.
From the trial programs behind finerenone, dapagliflozin, daprodustat, and tolvaptan to today's next-generation molecules.
Tell us a little about your kidney health and the study team will review it against every open protocol, with no cost and no obligation.
Written by the research team at the region's kidney research center, for patients, physicians, and sponsors alike.
Why a research institute owned by the treating nephrologists finds the patient, keeps the patient, and returns clean data. With the record to show for it.
Read the paper → From the blog Polycystic kidney disease: the research behind the first treatment, and Augusta's part in itWhat ADPKD is, what tolvaptan does, what comes next, and what families can do now.
Read the article →